The P2X7 Receptor is a Key Modulator of the PI3K/GSK3β/VEGF Signaling Network: Evidence in Experimental Neuroblastoma

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2015 Jan 27

PMID 25619831

Citations 101

Authors

F Amoroso

M Capece

A Rotondo

D Cangelosi

M Ferracin

A Franceschini

L Raffaghello

V Pistoia

L Varesio

E Adinolfi

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma (NB) is an aggressive pediatric tumor, responsible for 15% of cancer-related deaths in childhood, lacking an effective treatment in its advanced stages. The P2X7 receptor for extracellular ATP was associated to NB cell proliferation and recently emerged as a promoter of tumor engraftment, growth and vascularization. In an effort to identify new therapeutic options for neuroblastoma, we studied the role of P2X7 receptor in NB biology. We first analyzed the effect of P2X7 activation or down-modulation of the main biochemical ways involved in NB progression: the PI3K/Akt/GSK3β/MYCN and the HIF1α/VEGF pathways. In ACN human NB cells, P2X7 stimulation enhanced PI3K/Akt, while decreasing GSK3β activity. In the same model, P2X7 silencing or antagonist administration reduced the activity of PI3K/Akt and increased that of GSK3β, leading to a decrease in cellular glycogen stores. Similarly, P2X7 downmodulation caused a reduction in HIF1α levels and vascular endothelial growth factor (VEGF) secretion. Systemic administration of two different P2X7 antagonists (AZ10606120 or A740003) in nude/nude mice reduced ACN-derived tumor growth. An even stronger effect of P2X7 blockade was obtained in a syngeneic immune-competent neuroblastoma model: Neuro2A cells injected in AlbinoJ mice. Together with tumor regression, treatment with P2X7 antagonists caused downmodulation of the Akt/HIF1α axis, leading to reduced VEGF content and decreased vessel formation. Interestingly, in both experimental models, P2X7 antagonists strongly reduced the expression of the probably best-accepted oncogene in NB: MYCN. Finally, we associated P2X7 overexpression with poor prognosis in advanced-stage NB patients. Taken together, our data suggest that P2X7 receptor is an upstream regulator of the main signaling pathways involved in NB growth, metabolic activity and angiogenesis, and a promising therapeutic target for neuroblastoma treatment.

Citing Articles

Transcriptome Analysis Suggests PKD3 Regulates Proliferative Glucose Metabolism, Calcium Homeostasis and Microtubule Dynamics After MEF Spontaneous Immortalization.

Loaiza-Moss J, Braun U, Leitges M Int J Mol Sci. 2025; 26(2).

PMID: 39859313 PMC: 11765705. DOI: 10.3390/ijms26020596.

Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.

Zhang W, Pi X, Le Y, Li T Sci Rep. 2024; 14(1):31673.

PMID: 39738256 PMC: 11685580. DOI: 10.1038/s41598-024-81515-7.

Antagonism of the ATP-gated P2X7 receptor inhibits the proliferation of hepatocellular carcinoma cells.

Tantai X, Yang X, Liu X, Yang X Purinergic Signal. 2024; .

PMID: 39549156 DOI: 10.1007/s11302-024-10064-5.

Antifibrotic effect of the P2X7 receptor antagonist A740003 against acute myocardial infarction-induced fibrotic remodelling.

Almusallam N, Alonazi A, Bin Dayel A, Almubarak A, Ali R, Althakfi W Saudi Pharm J. 2024; 32(7):102102.

PMID: 39035363 PMC: 11258548. DOI: 10.1016/j.jsps.2024.102102.

Purinergic Ca Signaling as a Novel Mechanism of Drug Tolerance in BRAF-Mutant Melanoma.

Stauffer P, Brinkley J, Jacobson D, Quaranta V, Tyson D Cancers (Basel). 2024; 16(13).

PMID: 39001489 PMC: 11240618. DOI: 10.3390/cancers16132426.

References

Kang J, Rychahou P, Ishola T, Mourot J, Evers B, Chung D . N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene. 2008; 27(28):3999-4007. PMC: 2614290. DOI: 10.1038/onc.2008.15. View

Keystone E, Wang M, Layton M, Hollis S, McInnes I . Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012; 71(10):1630-5. DOI: 10.1136/annrheumdis-2011-143578. View

Ghalali A, Wiklund F, Zheng H, Stenius U, Hogberg J . Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis. 2014; 35(7):1547-55. DOI: 10.1093/carcin/bgu019. View

Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A . P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002; 99(2):706-8. DOI: 10.1182/blood.v99.2.706. View

Adinolfi E, Raffaghello L, Giuliani A, Cavazzini L, Capece M, Chiozzi P . Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012; 72(12):2957-69. DOI: 10.1158/0008-5472.CAN-11-1947. View

Fruman D, Rommel C . PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13(2):140-56. PMC: 3994981. DOI: 10.1038/nrd4204. View

Stock T, Bloom B, Wei N, Ishaq S, Park W, Wang X . Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012; 39(4):720-7. DOI: 10.3899/jrheum.110874. View

Maurer U, Preiss F, Brauns-Schubert P, Schlicher L, Charvet C . GSK-3 - at the crossroads of cell death and survival. J Cell Sci. 2014; 127(Pt 7):1369-78. DOI: 10.1242/jcs.138057. View

Williams E, Dunn S, James S, Johnson P, Cragg M, Glennie M . Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res. 2013; 19(13):3545-55. PMC: 3743027. DOI: 10.1158/1078-0432.CCR-12-3226. View

10.

Adinolfi E, Callegari M, Cirillo M, Pinton P, Giorgi C, Cavagna D . Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem. 2009; 284(15):10120-8. PMC: 2665066. DOI: 10.1074/jbc.M805805200. View

11.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

12.

Adinolfi E, Amoroso F, Giuliani A . P2X7 Receptor Function in Bone-Related Cancer. J Osteoporos. 2012; 2012:637863. PMC: 3431089. DOI: 10.1155/2012/637863. View

13.

Agani F, Jiang B . Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013; 13(3):245-51. DOI: 10.2174/1568009611313030003. View

14.

Hogarty M, Maris J . PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell. 2012; 21(2):145-7. DOI: 10.1016/j.ccr.2012.01.018. View

15.

Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R . A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer. 2010; 9:185. PMC: 2908582. DOI: 10.1186/1476-4598-9-185. View

16.

Chong J, Zheng G, Zhu X, Guo Y, Wang L, Ma C . Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. Biochem Biophys Res Commun. 2009; 391(1):498-504. DOI: 10.1016/j.bbrc.2009.11.087. View

17.

Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G . Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010; 70(3):855-8. DOI: 10.1158/0008-5472.CAN-09-3566. View

18.

Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I . ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis. 2014; 5:e1135. PMC: 3973218. DOI: 10.1038/cddis.2014.109. View

19.

Wu P, Lin Y, Chang C, Lu H, Chin C, Hsu T . Functional decreases in P2X7 receptors are associated with retinoic acid-induced neuronal differentiation of Neuro-2a neuroblastoma cells. Cell Signal. 2009; 21(6):881-91. DOI: 10.1016/j.cellsig.2009.01.036. View

20.

Baricordi O, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G . Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem. 1999; 274(47):33206-8. DOI: 10.1074/jbc.274.47.33206. View